Evidence map›Paper›PMID 37073955›Full record

ArticleeLife2023

Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells.

Julieta Martino, Sebastián Omar Siri, Nicolás Luis Calzetta, Natalia Soledad Paviolo, Cintia Garro, Maria F Pansa, Sofía Carbajosa, Aaron C Brown, José Luis Bocco, Israel Gloger and 4 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in eLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Unraveling the Molecular Mechanisms Underlying Spontaneous Multipolar Mitosis Through CIN-seq.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. The two sides of chromosomal instability: drivers and brakes in cancer.Signal transduction and targeted therapy · 2024
    Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

Julieta Martino *Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
Sebastián Omar Siri *Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.ORCID https://orcid.org/0000-0002-0945-5605
Nicolás Luis CalzettaFundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
Natalia Soledad PavioloFundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
Cintia GarroCentro de Investigaciones en Bioquímica Clínica e Inmunología, CIBICI-CONICET, Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina.
Maria F PansaCentro de Investigaciones en Bioquímica Clínica e Inmunología, CIBICI-CONICET, Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina.
Sofía CarbajosaCentro de Investigaciones en Bioquímica Clínica e Inmunología, CIBICI-CONICET, Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina.
Aaron C BrownCenter for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, United States.
José Luis BoccoCentro de Investigaciones en Bioquímica Clínica e Inmunología, CIBICI-CONICET, Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina.ORCID https://orcid.org/0000-0002-9682-1270
Israel GlogerGlaxoSmithKline-Trust in Science, Global Health R&D, Stevenage, United Kingdom.
Gerard DrewesGlaxoSmithKline-Trust in Science, Global Health R&D, Stevenage, United Kingdom.
Kevin P MadaussGlaxoSmithKline-Trust in Science, Global Health R&D, Upper Providence, United States.
Gastón SoriaCentro de Investigaciones en Bioquímica Clínica e Inmunología, CIBICI-CONICET, Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina.
Vanesa GottifrediFundación Instituto Leloir-CONICET, Buenos Aires, Argentina.ORCID https://orcid.org/0000-0001-9656-5951
Consejo Nacional de Investigaciones Científicas y Técnicas · ARGlaxoSmithKline (India) · INMaine Medical Center Research Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The trapping of Poly-ADP-ribose polymerase (PARP) on DNA caused by PARP inhibitors (PARPi) triggers acute DNA replication stress and synthetic lethality (SL) in BRCA2-deficient cells. Hence, DNA damage is accepted as a prerequisite for SL in BRCA2-deficient cells. In contrast, here we show that inhibiting ROCK in BRCA2-deficient cells triggers SL independently from acute replication stress. Such SL is preceded by polyploidy and binucleation resulting from cytokinesis failure. Such initial mitosis abnormalities are followed by other M phase defects, including anaphase bridges and abnormal mitotic figures associated with multipolar spindles, supernumerary centrosomes and multinucleation. SL was also triggered by inhibiting Citron Rho-interacting kinase, another enzyme that, similarly to ROCK, regulates cytokinesis. Together, these observations demonstrate that cytokinesis failure triggers mitotic abnormalities and SL in BRCA2-deficient cells. Furthermore, the prevention of mitotic entry by depletion of Early mitotic inhibitor 1 (EMI1) augmented the survival of BRCA2-deficient cells treated with ROCK inhibitors, thus reinforcing the association between M phase and cell death in BRCA2-deficient cells. This novel SL differs from the one triggered by PARPi and uncovers mitosis as an Achilles heel of BRCA2-deficient cells.

Indexed as

DNA DamageSynthetic Lethal MutationsAnaphaseBRCA2 ProteinHumansMitosisPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) Polymerasesrho-Associated KinasesBRCA2 ProteinPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) Polymerasesrho-Associated KinasesBRCA2cancer biologycancer cell linescell biologycytokinesis failuremitosisROCKsynthetic lethality

Identifiers

PMID37073955
PMCPMC10185344
OpenAlexW4366352629

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.